This is a major pipeline de-risking event for a clinical-stage biotech with a $244M market cap. Traders should watch for initial safety data by year-end 2026 as the next key catalyst. The stock may re-rate on the successful transition from preclinical to clinical development, but binary risk remains on eventual efficacy and safety readouts.
Price Chart
Executive Summary
Precision BioSciences dosed the first patient in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy. This is the first clinical gene-editing program for DMD, representing a significant pipeline milestone for this clinical-stage biotech. Initial safety data is expected by year-end 2026, providing a key near-term catalyst.
Key Facts
- First patient dosed in Phase 1/2 FUNCTION-DMD trial for PBGENE-DMD, the first clinical gene-editing program for Duchenne muscular dystrophy.
- PBGENE-DMD is designed to restore near full-length functional dystrophin, applicable to up to 60% of DMD patients with mutations in a key hot spot region.
- Initial safety data expected by year-end 2026.
- PBGENE-DMD has Orphan Drug Designation (July 2025) and Fast Track designation (February 2026) from the FDA.
- The program is eligible for a Priority Review Voucher (PRV) via the Rare Pediatric Disease program.
Financial Impact
No financial figures disclosed; this is a clinical milestone with no revenue impact. The event de-risks the pipeline and supports the company's valuation thesis as a clinical-stage gene editing company.
Risk Factors
- Clinical trial failure or safety issues could lead to significant downside.
- Dependence on successful enrollment and execution of the Phase 1/2 trial.
- No approved therapies for DMD that drive durable functional improvements; high unmet need but also high development risk.
- Potential dilution risk if the company needs to raise capital to fund ongoing trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-058512 |
| Document: 0001628280-26-058512-index.html | 0001628280-26-058512 |
| Document: 0001628280-26-058512.txt | 0001628280-26-058512 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | Institutional Cluster | $7.19 $6.36 | ▼ −11.54% | ▼ −10.82% | $6.41 (−10.85%) |
Aug 24, 2026 9w ago | 8-K | $8.45 $8.55 | ▲ +1.18% | ▲ +0.86% | $6.41 (−24.14%) |
Aug 6, 2026 11w ago | 8-K | $7.42 $7.49 | ▲ +0.94% | ▲ +0.33% | $6.41 (−13.61%) |
Jul 27, 2026 13w ago | 8-K | $7.25 $7.17 | ▼ −1.10% | ▼ −1.34% | $6.41 (−11.59%) |
Jul 1, 2026 16w ago | 8-K | $7.88 $8.18 | ▲ +3.81% | ▲ +3.94% | $6.41 (−18.65%) |
Jun 16, 2026 18w ago | 8-K | $6.50 $6.81 | ▲ +4.77% | ▲ +3.99% | $6.41 (−1.38%) |
May 27, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.41 (−15.55%) |
May 26, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.41 (−15.55%) |
May 5, 2026 24w ago | 8-K | $7.45 $7.52 | ▲ +0.94% | ▼ −0.45% | $6.41 (−13.96%) |
Apr 8, 2026 28w ago | DEFA14A | $5.99 $6.61 | ▲ +10.35% | ▲ +9.78% | $6.41 (+7.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers